Download PDF
Semin Reprod Med 2022; 40(01/02): 089-097
DOI: 10.1055/s-0041-1735629
Review Article

Contraception in Adolescents

Shandhini Raidoo
1   Department of Obstetrics, Gynecology, and Women's Health, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, Hawaii
,
Marit Pearlman Shapiro
1   Department of Obstetrics, Gynecology, and Women's Health, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, Hawaii
,
Bliss Kaneshiro 
1   Department of Obstetrics, Gynecology, and Women's Health, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, Hawaii
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

Adolescents are at risk for unwanted pregnancy when they become sexually active, and contraception is an important part of mitigating this risk. Use of contraceptive methods, and long-acting reversible contraceptive methods such as implants and intrauterine devices in particular, has increased among adolescents. Although sexual activity has declined and contraceptive use has increased among adolescents in the United States in recent years, the unintended pregnancy rate remains high. All of the currently available contraceptive methods are safe and effective for adolescents to use; however, adolescents may have specific concerns about side effect profiles and unscheduled bleeding that should be addressed during contraceptive counseling. Healthcare providers should prioritize adolescents' needs and preferences when approaching contraceptive counseling, and also consider the unique access and confidentiality issues that adolescents face when accessing contraception.

Keywords

adolescents - contraception - pregnancy - birth control


Publication History

Article published online:
09 September 2021

© 2021. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Kann L, McManus T, Harris WA. et al. Youth risk behavior surveillance - United States, 2017. MMWR Surveill Summ 2018; 67 (08) 1-114
    CrossrefPubMedGoogle Scholar
  • 2 Lindberg LD, Firestein L, Beavin C. Trends in U.S. adolescent sexual behavior and contraceptive use, 2006-2019. Contracept X 2021; 3: 100064
    CrossrefPubMedGoogle Scholar
  • 3 Potter JE, Stevenson AJ, Coleman-Minahan K. et al. Challenging unintended pregnancy as an indicator of reproductive autonomy. Contraception 2019; 100 (01) 1-4
    CrossrefPubMedGoogle Scholar
  • 4 Santelli J, Rochat R, Hatfield-Timajchy K. et al; Unintended Pregnancy Working Group. The measurement and meaning of unintended pregnancy. Perspect Sex Reprod Health 2003; 35 (02) 94-101
    CrossrefPubMedGoogle Scholar
  • 5 Finer LB, Zolna MR. Declines in unintended pregnancy in the United States, 2008-2011. N Engl J Med 2016; 374 (09) 843-852
    CrossrefPubMedGoogle Scholar
  • 6 Martin JA, Hamilton BE, Osterman MJK, Driscoll AK. Births: final data for 2018. Natl Vital Stat Rep 2019; 68 (13) 1-47
    PubMedGoogle Scholar
  • 7 Sedgh G, Finer LB, Bankole A, Eilers MA, Singh S. Adolescent pregnancy, birth, and abortion rates across countries: levels and recent trends. J Adolesc Health 2015; 56 (02) 223-230
    CrossrefPubMedGoogle Scholar
  • 8 Kavanaugh ML, Jerman J. Contraceptive method use in the United States: trends and characteristics between 2008, 2012 and 2014. Contraception 2018; 97 (01) 14-21
    CrossrefPubMedGoogle Scholar
  • 9 Lindberg LD, Santelli JS, Desai S. Changing patterns of contraceptive use and the decline in rates of pregnancy and birth among U.S. adolescents, 2007-2014. J Adolesc Health 2018; 63 (02) 253-256
    CrossrefPubMedGoogle Scholar
  • 10 Raidoo S, Tschann M, Elia J, Kaneshiro B, Soon R. Dual-method contraception among adolescents and young people: are long-acting reversible contraception users different? A qualitative study. J Pediatr Adolesc Gynecol 2020; 33 (01) 45-52
    CrossrefPubMedGoogle Scholar
  • 11 American College of Obstetricians and Gynecologists' Committee on Adolescent Health Care. The initial reproductive health visit: ACOG committee opinion, number 811. Obstet Gynecol 2020; 136 (04) e70-e80
    CrossrefPubMedGoogle Scholar
  • 12 Ford C, English A, Sigman G. Confidential health care for adolescents: position paper for the society for adolescent medicine. J Adolesc Health 2004; 35 (02) 160-167
    CrossrefPubMedGoogle Scholar
  • 13 Leichliter JS, Copen C, Dittus PJ. Confidentiality issues and use of sexually transmitted disease services among sexually experienced persons aged 15-25 years - United States, 2013-2015. MMWR Morb Mortal Wkly Rep 2017; 66 (09) 237-241
    CrossrefPubMedGoogle Scholar
  • 14 Braverman PK, Breech L. Committee on Adolescence. American Academy of Pediatrics. Clinical report–gynecologic examination for adolescents in the pediatric office setting. Pediatrics 2010; 126 (03) 583-590
    CrossrefPubMedGoogle Scholar
  • 15 Gubrium AC, Mann ES, Borrero S. et al. Realizing reproductive health equity needs more than long-acting reversible contraception (LARC). Am J Public Health 2016; 106 (01) 18-19
    CrossrefPubMedGoogle Scholar
  • 16 Gilliam ML, Neustadt A, Gordon R. A call to incorporate a reproductive justice agenda into reproductive health clinical practice and policy. Contraception 2009; 79 (04) 243-246
    CrossrefPubMedGoogle Scholar
  • 17 Curtis KM, Tepper NK, Jatlaoui TC. et al. U.S. medical eligibility criteria for contraceptive use, 2016. MMWR Recomm Rep 2016; 65 (03) 1-103
    CrossrefPubMedGoogle Scholar
  • 18 Moreau C, Cleland K, Trussell J. Contraceptive discontinuation attributed to method dissatisfaction in the United States. Contraception 2007; 76 (04) 267-272
    CrossrefPubMedGoogle Scholar
  • 19 Bahamondes L, Valeria Bahamondes M, Shulman LP. Non-contraceptive benefits of hormonal and intrauterine reversible contraceptive methods. Hum Reprod Update 2015; 21 (05) 640-651
    CrossrefPubMedGoogle Scholar
  • 20 Committee on Adolescent Health Care Long-Acting Reversible Contraception Working Group, The American College of Obstetricians and Gynecologists. Committee opinion no. 539: adolescents and long-acting reversible contraception: implants and intrauterine devices. Obstet Gynecol 2012; 120 (04) 983-988
    CrossrefPubMedGoogle Scholar
  • 21 Committee on Adolescence. Contraception for adolescents. Pediatrics 2014; 134 (04) e1244-e1256
    CrossrefPubMedGoogle Scholar
  • 22 Finer LB, Jerman J, Kavanaugh ML. Changes in use of long-acting contraceptive methods in the United States, 2007-2009. Fertil Steril 2012; 98 (04) 893-897
    CrossrefPubMedGoogle Scholar
  • 23 Martinez GM, Abma JC. Sexual activity and contraceptive use among teenagers aged 15-19 in the United States, 2015-2017. NCHS Data Brief 2020; (366) 1-8
    PubMedGoogle Scholar
  • 24 Trussell J. Contraceptive failure in the United States. Contraception 2011; 83 (05) 397-404
    CrossrefPubMedGoogle Scholar
  • 25 McNicholas C, Maddipati R, Zhao Q, Swor E, Peipert JF. Use of the etonogestrel implant and levonorgestrel intrauterine device beyond the U.S. Food and Drug Administration-approved duration. Obstet Gynecol 2015; 125 (03) 599-604
    CrossrefPubMedGoogle Scholar
  • 26 nexplanon_pi.pdf. Accessed April 26, 2021 at: https://www.merck.com/product/usa/pi_circulars/n/nexplanon/nexplanon_pi.pdf
    PubMed
  • 27 Mansour D, Korver T, Marintcheva-Petrova M, Fraser IS. The effects of Implanon on menstrual bleeding patterns. Eur J Contracept Reprod Health Care 2008; 13 (Suppl. 01) 13-28
    CrossrefPubMedGoogle Scholar
  • 28 Deokar AM, Jackson W, Omar HA. Menstrual bleeding patterns in adolescents using etonogestrel (ENG) implant. Int J Adolesc Med Health 2011; 23 (01) 75-77
    CrossrefPubMedGoogle Scholar
  • 29 Hou MY, McNicholas C, Creinin MD. Combined oral contraceptive treatment for bleeding complaints with the etonogestrel contraceptive implant: a randomised controlled trial. Eur J Contracept Reprod Health Care 2016; 21 (05) 361-366
    CrossrefPubMedGoogle Scholar
  • 30 Edelman AB, Kaneshiro B, Simmons KB. et al. Treatment of unfavorable bleeding patterns in contraceptive implant users: a randomized controlled trial. Obstet Gynecol 2020; 136 (02) 323-332
    CrossrefPubMedGoogle Scholar
  • 31 Mansour D, Bahamondes L, Critchley H, Darney P, Fraser IS. The management of unacceptable bleeding patterns in etonogestrel-releasing contraceptive implant users. Contraception 2011; 83 (03) 202-210
    CrossrefPubMedGoogle Scholar
  • 32 Long-Acting Reversible Contraception: Implants and Intrauterine Devices. Accessed April 26, 2021 at: https://www.acog.org/en/clinical/clinical-guidance/practice-bulletin/articles/2017/11/long-acting-reversible-contraception-implants-and-intrauterine-devices
    PubMedGoogle Scholar
  • 33 Natavio MF, Taylor D, Lewis RA. et al. Temporal changes in cervical mucus after insertion of the levonorgestrel-releasing intrauterine system. Contraception 2013; 87 (04) 426-431
    CrossrefPubMedGoogle Scholar
  • 34 208224s000lbl.pdf. Accessed April 26, 2021 at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208224s000lbl.pdf
    PubMed
  • 35 203159s000lbl.pdf. Accessed April 26, 2021 at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203159s000lbl.pdf
    PubMed
  • 36 Goldthwaite LM, Creinin MD. Comparing bleeding patterns for the levonorgestrel 52 mg, 19.5 mg, and 13.5 mg intrauterine systems. Contraception 2019; 100 (02) 128-131
    CrossrefPubMedGoogle Scholar
  • 37 Mirena_PI.pdf. Accessed April 26, 2021 at: https://labeling.bayerhealthcare.com/html/products/pi/Mirena_PI.pdf
    PubMed
  • 38 Schwartz BI, Alexander M, Breech LL. Intrauterine device use in adolescents with disabilities. Pediatrics 2020; 146 (02) e20200016
    CrossrefPubMedGoogle Scholar
  • 39 Turok DK, Gero A, Simmons RG. et al. Levonorgestrel vs. copper intrauterine devices for emergency contraception. N Engl J Med 2021; 384 (04) 335-344
    CrossrefPubMedGoogle Scholar
  • 40 Wu JP, Pickle S. Extended use of the intrauterine device: a literature review and recommendations for clinical practice. Contraception 2014; 89 (06) 495-503
    CrossrefPubMedGoogle Scholar
  • 41 Kaneshiro B, Aeby T. Long-term safety, efficacy, and patient acceptability of the intrauterine copper T-380A contraceptive device. Int J Womens Health 2010; 2: 211-220
    CrossrefPubMedGoogle Scholar
  • 42 Ortiz ME, Croxatto HB. Copper-T intrauterine device and levonorgestrel intrauterine system: biological bases of their mechanism of action. Contraception 2007; 75 (6, Suppl): S16-S30
    CrossrefPubMedGoogle Scholar
  • 43 Milsom I, Andersson K, Jonasson K, Lindstedt G, Rybo G. The influence of the Gyne-T 380S IUD on menstrual blood loss and iron status. Contraception 1995; 52 (03) 175-179
    CrossrefPubMedGoogle Scholar
  • 44 Schmidt EO, James A, Curran KM, Peipert JF, Madden T. Adolescent experiences with intrauterine devices: a qualitative study. J Adolesc Health 2015; 57 (04) 381-386
    CrossrefPubMedGoogle Scholar
  • 45 Grunloh DS, Casner T, Secura GM, Peipert JF, Madden T. Characteristics associated with discontinuation of long-acting reversible contraception within the first 6 months of use. Obstet Gynecol 2013; 122 (06) 1214-1221
    CrossrefPubMedGoogle Scholar
  • 46 Turok DK, Godfrey EM, Wojdyla D, Dermish A, Torres L, Wu SC. Copper T380 intrauterine device for emergency contraception: highly effective at any time in the menstrual cycle. Hum Reprod 2013; 28 (10) 2672-2676
    CrossrefPubMedGoogle Scholar
  • 47 Friedman JO. Factors associated with contraceptive satisfaction in adolescent women using the IUD. J Pediatr Adolesc Gynecol 2015; 28 (01) 38-42
    CrossrefPubMedGoogle Scholar
  • 48 Jatlaoui TC, Riley HEM, Curtis KM. The safety of intrauterine devices among young women: a systematic review. Contraception 2017; 95 (01) 17-39
    CrossrefPubMedGoogle Scholar
  • 49 O'Flynn O'Brien KL, Akers AY, Perriera LK, Schreiber CA, Garcia-Espana JF, Sonalkar S. Intrauterine device insertion procedure duration in adolescent and young adult women. J Pediatr Adolesc Gynecol 2019; 32 (03) 312-315
    CrossrefPubMedGoogle Scholar
  • 50 Gemzell-Danielsson K, Schellschmidt I, Apter D. A randomized, phase II study describing the efficacy, bleeding profile, and safety of two low-dose levonorgestrel-releasing intrauterine contraceptive systems and Mirena. Fertil Steril 2012; 97 (03) 616-22.e1 , 3
    CrossrefPubMedGoogle Scholar
  • 51 Faúndes A, Telles E, Cristofoletti ML, Faúndes D, Castro S, Hardy E. The risk of inadvertent intrauterine device insertion in women carriers of endocervical Chlamydia trachomatis . Contraception 1998; 58 (02) 105-109
    CrossrefPubMedGoogle Scholar
  • 52 ACOG Practice Bulletin No. ACOG Practice Bulletin No. 121: long-acting reversible contraception: Implants and intrauterine devices. Obstet Gynecol 2011; 118 (01) 184-196
    CrossrefPubMedGoogle Scholar
  • 53 Mohllajee AP, Curtis KM, Peterson HB. Does insertion and use of an intrauterine device increase the risk of pelvic inflammatory disease among women with sexually transmitted infection? A systematic review. Contraception 2006; 73 (02) 145-153
    CrossrefPubMedGoogle Scholar
  • 54 Okusanya BO, Oduwole O, Effa EE. Immediate postabortal insertion of intrauterine devices. Cochrane Database Syst Rev 2014; (07) CD001777
    PubMedGoogle Scholar
  • 55 Polaneczky M, Liblanc M. Long-term depot medroxyprogesterone acetate (Depo-Provera) use in inner-city adolescents. J Adolesc Health 1998; 23 (02) 81-88
    CrossrefPubMedGoogle Scholar
  • 56 Jain J, Jakimiuk AJ, Bode FR, Ross D, Kaunitz AM. Contraceptive efficacy and safety of DMPA-SC. Contraception 2004; 70 (04) 269-275
    CrossrefPubMedGoogle Scholar
  • 57 Ott MA, Sucato GS. Committee on Adolescence. Contraception for adolescents. Pediatrics 2014; 134 (04) e1257-e1281
    CrossrefPubMedGoogle Scholar
  • 58 Lopez LM, Ramesh S, Chen M. et al. Progestin-only contraceptives: effects on weight. Cochrane Database Syst Rev 2016; (08) CD008815
    PubMedGoogle Scholar
  • 59 Bonny AE, Ziegler J, Harvey R, Debanne SM, Secic M, Cromer BA. Weight gain in obese and nonobese adolescent girls initiating depot medroxyprogesterone, oral contraceptive pills, or no hormonal contraceptive method. Arch Pediatr Adolesc Med 2006; 160 (01) 40-45
    CrossrefPubMedGoogle Scholar
  • 60 Westhoff C. Bone mineral density and DMPA. J Reprod Med 2002; 47 (9, Suppl): 795-799
    PubMedGoogle Scholar
  • 61 Committee Opinion No. Committee Opinion No. 602: Depot medroxyprogesterone acetate and bone effects. Obstet Gynecol 2014; 123 (06) 1398-1402
    CrossrefPubMedGoogle Scholar
  • 62 Maximizing the use of the progestin minipill. Contracept Technol Update 1999; 20 (02) 19-21
    PubMedGoogle Scholar
  • 63 Rivera R, Yacobson I, Grimes D. The mechanism of action of hormonal contraceptives and intrauterine contraceptive devices. Am J Obstet Gynecol 1999; 181 (5, Pt 1): 1263-1269
    CrossrefPubMedGoogle Scholar
  • 64 Drospirenone (Slynd) - a new progestin-only oral contraceptive. JAMA 2020; 323 (19) 1963-1964
    CrossrefPubMedGoogle Scholar
  • 65 Bitzer J, Simon JA. Current issues and available options in combined hormonal contraception. Contraception 2011; 84 (04) 342-356
    CrossrefPubMedGoogle Scholar
  • 66 Curtis KM, Jatlaoui TC, Tepper NK. et al. U.S. selected practice recommendations for contraceptive use, 2016. MMWR Recomm Rep 2016; 65 (04) 1-66
    CrossrefPubMedGoogle Scholar
  • 67 Gallo MF, Lopez LM, Grimes DA, Carayon F, Schulz KF, Helmerhorst FM. Combination contraceptives: effects on weight. Cochrane Database Syst Rev 2014; (01) CD003987
    PubMedGoogle Scholar
  • 68 Noncontraceptive Uses of Hormonal Contraceptives | ACOG. Accessed May 3, 2021 at: https://www.acog.org/clinical/clinical-guidance/practice-bulletin/articles/2010/01/noncontraceptive-uses-of-hormonal-contraceptives
    PubMedGoogle Scholar
  • 69 Barrionuevo P, Nabhan M, Altayar O. et al. Treatment options for hirsutism: a systematic review and network meta-analysis. J Clin Endocrinol Metab 2018; 103 (04) 1258-1264
    CrossrefPubMedGoogle Scholar
  • 70 Lopez LM, Kaptein AA, Helmerhorst FM. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev 2012; (02) CD006586
    PubMedGoogle Scholar
  • 71 Beral V, Doll R, Hermon C, Peto R, Reeves G. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 2008; 371 (9609): 303-314
    CrossrefPubMedGoogle Scholar
  • 72 Bosetti C, Negri E, Trichopoulos D. et al. Long-term effects of oral contraceptives on ovarian cancer risk. Int J Cancer 2002; 102 (03) 262-265
    CrossrefPubMedGoogle Scholar
  • 73 Mueck AO, Seeger H, Rabe T. Hormonal contraception and risk of endometrial cancer: a systematic review. Endocr Relat Cancer 2010; 17 (04) R263-R271
    CrossrefPubMedGoogle Scholar
  • 74 Peipert JF, Zhao Q, Allsworth JE. et al. Continuation and satisfaction of reversible contraception. Obstet Gynecol 2011; 117 (05) 1105-1113
    CrossrefPubMedGoogle Scholar
  • 75 Serfaty D. Medical aspects of oral contraceptive discontinuation. Adv Contracept 1992; 8 (Suppl. 01) 21-33
    CrossrefPubMedGoogle Scholar
  • 76 Molloy GJ, Graham H, McGuinness H. Adherence to the oral contraceptive pill: a cross-sectional survey of modifiable behavioural determinants. BMC Public Health 2012; 12 (01) 838
    CrossrefPubMedGoogle Scholar
  • 77 021180s048lbl.pdf. Accessed May 3, 2021 at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021180s048lbl.pdf
    PubMed
  • 78 Sucato GS, Land SR, Murray PJ, Cecchini R, Gold MA. Adolescents' experiences using the contraceptive patch versus pills. J Pediatr Adolesc Gynecol 2011; 24 (04) 197-203
    CrossrefPubMedGoogle Scholar
  • 79 Logsdon S, Richards J, Omar HA. Long-term evaluation of the use of the transdermal contraceptive patch in adolescents. ScientificWorldJournal 2004; 4: 512-516
    CrossrefPubMedGoogle Scholar
  • 80 Galzote RM, Rafie S, Teal R, Mody SK. Transdermal delivery of combined hormonal contraception: a review of the current literature. Int J Womens Health 2017; 9: 315-321
    CrossrefPubMedGoogle Scholar
  • 81 Zieman M, Guillebaud J, Weisberg E, Shangold GA, Fisher AC, Creasy GW. Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: the analysis of pooled data. Fertil Steril 2002; 77 (2, Suppl 2) S13-S18
    CrossrefPubMedGoogle Scholar
  • 82 McNicholas C, Zhao Q, Secura G, Allsworth JE, Madden T, Peipert JF. Contraceptive failures in overweight and obese combined hormonal contraceptive users. Obstet Gynecol 2013; 121 (03) 585-592
    CrossrefPubMedGoogle Scholar
  • 83 Shimoni N, Westhoff C. Review of the vaginal contraceptive ring (NuvaRing). J Fam Plann Reprod Health Care 2008; 34 (04) 247-250
    CrossrefPubMedGoogle Scholar
  • 84 Gilliam ML, Neustadt A, Kozloski M, Mistretta S, Tilmon S, Godfrey E. Adherence and acceptability of the contraceptive ring compared with the pill among students: a randomized controlled trial. Obstet Gynecol 2010; 115 (03) 503-510
    CrossrefPubMedGoogle Scholar
  • 85 Carey AS, Chiappetta L, Tremont K, Murray PJ, Gold MA. The contraceptive vaginal ring: female adolescents' knowledge, attitudes and plans for use. Contraception 2007; 76 (06) 444-450
    CrossrefPubMedGoogle Scholar
  • 86 Terrell LR, Tanner AE, Hensel DJ, Blythe MJ, Fortenberry JD. Acceptability of the vaginal contraceptive ring among adolescent women. J Pediatr Adolesc Gynecol 2011; 24 (04) 204-210
    CrossrefPubMedGoogle Scholar
  • 87 Archer DF, Merkatz RB, Bahamondes L. et al. Efficacy of the 1-year (13-cycle) segesterone acetate and ethinylestradiol contraceptive vaginal system: results of two multicentre, open-label, single-arm, phase 3 trials. Lancet Glob Health 2019; 7 (08) e1054-e1064
    CrossrefPubMedGoogle Scholar
  • 88 Vasilenko SA, Kreager DA, Lefkowitz ES. Gender, contraceptive attitudes, and condom use in adolescent romantic relationships: a dyadic approach. J Res Adolesc 2015; 25 (01) 51-62
    CrossrefPubMedGoogle Scholar
  • 89 Goldstein RL, Upadhyay UD, Raine TR. With pills, patches, rings, and shots: who still uses condoms? A longitudinal cohort study. J Adolesc Health 2013; 52 (01) 77-82
    CrossrefPubMedGoogle Scholar
  • 90 Tyler CP, Whiteman MK, Kraft JM. et al. Dual use of condoms with other contraceptive methods among adolescents and young women in the United States. J Adolesc Health 2014; 54 (02) 169-175
    CrossrefPubMedGoogle Scholar
  • 91 Eisenberg DL, Allsworth JE, Zhao Q, Peipert JF. Correlates of dual-method contraceptive use: an analysis of the National Survey of Family Growth (2006-2008). Infect Dis Obstet Gynecol 2012; 2012: 717163
    CrossrefPubMedGoogle Scholar
  • 92 Morroni C, Heartwell S, Edwards S, Zieman M, Westhoff C. The impact of oral contraceptive initiation on young women's condom use in 3 American cities: missed opportunities for intervention. PLoS One 2014; 9 (07) e101804
    CrossrefPubMedGoogle Scholar
  • 93 Bullock H, Steele S, Kurata N. et al. Pharmacy access to ulipristal acetate in Hawaii: is a prescription enough?. Contraception 2016; 93 (05) 452-454
    CrossrefPubMedGoogle Scholar
  • 94 Cleland K, Bass J, Doci F, Foster AM. Access to emergency contraception in the over-the-counter era. Womens Health Issues 2016; 26 (06) 622-627
    CrossrefPubMedGoogle Scholar
  • 95 Chau VM, Stamm CA, Borgelt L. et al. Barriers to single-dose levonorgestrel-only emergency contraception access in retail pharmacies. Womens Health Issues 2017; 27 (05) 518-522
    CrossrefPubMedGoogle Scholar
  • 96 Mestad R, Secura G, Allsworth JE, Madden T, Zhao Q, Peipert JF. Acceptance of long-acting reversible contraceptive methods by adolescent participants in the Contraceptive CHOICE Project. Contraception 2011; 84 (05) 493-498
    CrossrefPubMedGoogle Scholar
  • 97 Ricketts S, Klingler G, Schwalberg R. Game change in Colorado: widespread use of long-acting reversible contraceptives and rapid decline in births among young, low-income women. Perspect Sex Reprod Health 2014; 46 (03) 125-132
    CrossrefPubMedGoogle Scholar
  • 98 Sanders JN, Myers K, Gawron LM, Simmons RG, Turok DK. Contraceptive method use during the community-wide HER salt lake contraceptive initiative. Am J Public Health 2018; 108 (04) 550-556
    CrossrefPubMedGoogle Scholar
  • 99 An Overview of Consent to Reproductive Health Services by Young People. Guttmacher Institute. Published March 14, 2016. Accessed May 2, 2021 at: https://www.guttmacher.org/state-policy/explore/overview-minors-consent-law
    PubMedGoogle Scholar
  • 100 Committee opinion no. 615: access to contraception. Obstet Gynecol 2015; 125 (01) 250-255
    CrossrefPubMedGoogle Scholar
  • 101 Family Planning Annual Report: 2019 National Summary. Published online 2019: 138
    PubMedGoogle Scholar
  • 102 After Title X Regulation Changes: Difficult Questions For Policymakers And Providers | Health Affairs Blog. Accessed May 4, 2021 at: https://www.healthaffairs.org/do/10.1377/hblog20190923.813004/full/
    PubMedGoogle Scholar
  • 103 Meeting the Sexual and Reproductive Health Needs of Adolescents in School-Based Health Centers. Guttmacher Institute. Published April 21, 2015. Accessed May 2, 2021 at: https://www.guttmacher.org/gpr/2015/04/meeting-sexual-and-reproductive-health-needs-adolescents-school-based-health-centers
    PubMed
  • 104 Summit AK, Friedman E, Stein TB, Gold M. Integration of onsite long-acting reversible contraception services into school-based health centers. J Sch Health 2019; 89 (03) 226-231
    CrossrefPubMedGoogle Scholar
  • 105 Gilmore K, Hoopes AJ, Cady J, Amies Oelschlager A-M, Prager S, Vander Stoep A. Providing long-acting reversible contraception services in Seattle school-based health centers: key themes for facilitating implementation. J Adolesc Health 2015; 56 (06) 658-665
    CrossrefPubMedGoogle Scholar